Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies (Q37598141)

21 August 2017

1 reference

title

Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies (English)

1 reference

21 August 2017

1 reference

1 reference

Bertrand Coiffier

1

1 reference

PubMed ID

19757306

21 August 2017

Vincent Ribrag

series ordinal

2

1 reference

21 August 2017

1 December 2009

1 reference

21 August 2017

1 reference

21 August 2017

50

1 reference

21 August 2017

12

1 reference

21 August 2017

1916-1930

1 reference

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

21 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Growing roles for the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Curcumin disrupts the Mammalian target of rapamycin-raptor complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

When translation meets transformation: the mTOR story

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Current treatment approaches for mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Is mTOR inhibition a therapeutic option in chronic lymphocytic leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Downstream effectors of oncogenic ras in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Antileukemic activity of rapamycin in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903207548

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.28.727

Identifiers

DOI

10.3109/10428190903207548

1 reference

21 August 2017

1 reference

PubMed ID

19757306